Clinical Trials Browser

Completed × Recurrence × Everolimus × Clear all

Neoplasm Metastasis, Neoplasms, Recurrence

NCT00081874 2025-04-27

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT01523977 2024-07-18

CRAD001NUS175T

Phase 1 Completed

22 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1/2 Completed

64 enrolled 29 charts

CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT01624766 2021-02-25

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Phase 1 Completed

57 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01031381 2016-08-30

RADBEV

Phase 2 Completed

50 enrolled 7 charts

Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Recurrence

NCT00756340 2015-10-14

A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

Phase 1 Completed

16 enrolled

CNS

Recurrence, Central Nervous System Neoplasms

NCT00187174 2015-03-04

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Phase 1 Completed

41 enrolled

CNSSarcoma

Brain Neoplasms, Neoplasms, Recurrence, Rhabdomyosarcoma, Sarcoma

NCT00967044 2015-02-26

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Phase 1/2 Completed

31 enrolled 6 charts

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT01079481 2013-05-30

Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer

Phase 1 Completed

21 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

Clinical Trials

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

CRAD001NUS175T

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

RADBEV

A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer